AI assistant
CorMedix Inc. — Director's Dealing 2015
Mar 3, 2015
32333_dirs_2015-03-03_752873ca-d958-4985-b449-7c6673e5bce5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2015-03-02
Reporting Person: Lefkowitz Steven W (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-03-02 | Stock Option (right to buy) | $5.62 | A | 50000 | Acquired | 2025-03-01 | Common Stock, $0.001 par value per share (50000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, $0.001 par value per share | 124035 | Direct |
| Common Stock, $0.001 par value per share | 174741 | Indirect |
| Common Stock, $0.001 par value per share | 10000 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $2.02 | 2024-01-09 | Common Stock, $0.001 par value per share (200000) | 200000 | Direct |
| Stock Option (right to buy) | $2.02 | 2024-01-09 | Common Stock, $0.001 par value per share (30000) | 30000 | Direct |
| Swries C-3 Non-Voting Convertible Preferred Stock | $1 | Common Stock, $0.001 par value per share (45000) | 4500 | Direct | |
| Warrant (right to purchase Common Stock) | $1.25 | 2020-01-08 | Common Stock, $0.001 par value per share (22500) | 22500 | Direct |
| Series C-3 Non-Voting Convertible Preferred Stock | $1 | Common Stock, $0.001 par value per share (30000) | 3000 | Indirect | |
| Warrant (right to purchase Common Stock) | $1.25 | 2020-01-08 | Common Stock, $0.001 par value per share (15000) | 15000 | Indirect |
| Warrant (right to purchase Common Stock) | $3.4375 | 2015-03-24 | Common Stock, $0.001 par value per share (5000) | 5000 | Direct |
| Stock Option (right to buy) | $0.9 | 2023-03-20 | Common Stock, $0.001 par value per share (120000) | 120000 | Direct |
| Stock Option (right to buy) | $0.68 | 2022-12-05 | Common Stock, $0.001 par value per share (150000) | 150000 | Direct |
| Stock Option (right to buy) | $0.29 | 2022-01-06 | Common Stock, $0.001 par value per share (30000) | 30000 | Direct |
| Stock Option (right to buy) | $1.1 | 2021-08-11 | Common Stock, $0.001 par value per share (30000) | 30000 | Direct |
| Warrant (right to purchase Common Stock) | $3.4375 | 2015-03-24 | Common Stock, $0.001 par value per share (19536) | 19536 | Direct |
| Warrant (right to purchase Common Stock) | $3.4375 | 2015-03-24 | Common Stock, $0.001 par value per share (7900) | 7900 | Direct |
Footnotes
F1: The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).
F2: The options vested 100% on January 10, 2014.
F3: On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
F4: On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
F5: These options vest quarterly over two years beginning June 13, 2013.
F6: These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occuured on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
F7: The options vest in full on the first anniversary of the date of grant.
F8: The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
F9: The warrants were issued as part of the Company's initial public offering in March 2010 and were exercisable beginning six months after the effective date of hte Company's registration statement related thereto.